Breaking News

Tweet TWEET

Questcor Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

   Questcor Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

PR Newswire

ANAHEIM, Calif., Jan. 3, 2013

ANAHEIM, Calif., Jan. 3, 2013 /PRNewswire/ --Questcor Pharmaceuticals, Inc.
(NASDAQ: QCOR) announced today that executive management is scheduled to
present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco,
California, on Thursday, January 10, 2013 at 9:00 a.m. PT / 12:00 p.m. ET.

A live webcast with accompanying slide presentation, and subsequent archived
replay of the presentation will be accessible at
http://ir.questcor.com/events.cfm. The replay will be available for
approximately 90 days after the event.

About Questcor


Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
treatment of patients with serious, difficult-to-treat autoimmune and
inflammatory disorders. Questcor's primary product is H.P. Acthar^® Gel
(repository corticotropin injection), an injectable drug that is approved by
the FDA for the treatment of 19 indications. Of these 19 indications,
Questcor currently generates substantially all of its net sales from three
indications: the treatment of proteinuria in idiopathic types of nephrotic
syndrome, the treatment of acute exacerbations of multiple sclerosis in
adults, and the treatment of infantile spasms in children under two years of
age. With respect to nephrotic syndrome, the FDA has approved Acthar to
"induce a diuresis or a remission of proteinuria in the nephrotic syndrome
without uremia of the idiopathic type or that due to lupus erythematosus."
Questcor has also launched a pilot effort in rheumatology, as Acthar is
approved for several rheumatology-related conditions including
Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is
also exploring the possibility of developing markets for other on-label
indications and the possibility of pursuing FDA approval of additional
indications not currently on the Acthar label where there is high unmet
medical need. For more information about Questcor, please visit
www.questcor.com.

SOURCE Questcor Pharmaceuticals, Inc.

Website: http://www.questcor.com
Contact: EVC Group, Gregory Gin/Patty Eisenhaur,
+1-646-445-4801/+1-951-316-0577 or Janine McCargo, +1-646-688-0425 or Doug
Sherk, +1-415-568-4887
 
Press spacebar to pause and continue. Press esc to stop.